There will be no crowded lobbies or $100 chair rentals at this year’s J.P. Morgan Healthcare Conference. But the trillion-dollar life sciences industry’s biggest annual meeting, forced onto Zoom by Omicron, will still attract attention from around the world as investors, executives, and others look to answer critical questions about the future of sectors like biotech and health tech.
Is there a second act for mRNA companies? Was teletherapy just a pandemic fad? Can Biogen salvage its foundering treatment for Alzheimer’s disease? And will 2022 be the year of the buyout? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment